AssetMark Inc
BCYC

AssetMark Inc’s Bicycle Therapeutics BCYC Stock Holding History

AssetMark Inc’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.73K Sell
1,588
-2,630
-62% -$12.1K ﹤0.01% 2592
2026
Q1 		$19.6K Buy
4,218
+590
+16% +$3.37K ﹤0.01% 2066
2025
Q4 		$25.7K Buy
3,628
+3
+0.1% +$22 ﹤0.01% 1923
2025
Q3 		$28.1K Buy
3,625
+1,552
+75% +$11.7K ﹤0.01% 1830
2025
Q2 		$14.4K Buy
2,073
+791
+62% +$6.3K ﹤0.01% 1877
2025
Q1 		$10.9K Buy
1,282
+22
+2% +$259 ﹤0.01% 1835
2024
Q4 		$17.6K Sell
1,260
-259
-17% -$5.55K ﹤0.01% 1683
2024
Q3 		$34.4K Buy
+1,519
New +$35K ﹤0.01% 1380

Other funds holding BCYC

PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

AssetMark Inc's BCYC Position: Q2 2026 in Review

AssetMark Inc reduced its Bicycle Therapeutics (BCYC) stake by 62% in Q2 2026, selling an estimated $12.1K and leaving 1,588 shares worth $6.73K. The position accounts for ﹤0.01% of the portfolio, ranked #2592.

AssetMark Inc first reported a position in BCYC in Q3 2024 and has held it in 8 quarters since. The position peaked at $34.4K in Q3 2024. 19 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • AssetMark Inc held 1,588 shares of Bicycle Therapeutics worth $6.73K as of Q2 2026.
  • AssetMark Inc sold 2,630 Bicycle Therapeutics shares in Q2 2026, an estimated $12.1K.
  • Bicycle Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2592 holding.
  • AssetMark Inc first reported a position in Bicycle Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • AssetMark Inc's Bicycle Therapeutics position peaked at $34.4K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.